Eli Lilly and Company - Cost of Goods Sold Including Depreciation and Amortization

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Cost-of-Goods-Sold-Including-Depreciation-and-Amortization" stands at 10.08 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Eli Lilly and Company's third quarter result of 3.01 Billion USD for the item "Cost of Goods Sold Including Depreciation and Amortization" represents an increase of 22.90 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 3.01 Billion USD for the item "Cost of Goods Sold Including Depreciation and Amortization" represents an increase of 38.58 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 10.08 Billion USD for the item "Cost of Goods Sold Including Depreciation and Amortization" represents an increase of 9.06 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 29.24 percent compared to the value the year prior.
The 1 year change in percent is 29.24.
The 3 year change in percent is 41.39.
The 5 year change in percent is 99.84.
The 10 year change in percent is 105.75.

The Serie's long term average value is 5.94 Billion United States Dollars. It's latest available value, on 09/30/2025, is 69.82 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2019, to it's latest available value, on 09/30/2025, is +113.59%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.